<< Back to Results
SWOG S0600 - Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second Line therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX (Accrual suspended 6/6/08).
Clinical Trial Categories
- The Rosenfeld Cancer Center at 215-481-2402
- The Rosenfeld Cancer Center